Experience of myocardial infarction in a Glasgow HIV cohort by S English et al.
BioMed Central
Page 1 of 1
(page number not for citation purposes)
Journal of the International AIDS 
Society
Open AccessPoster presentation
Experience of myocardial infarction in a Glasgow HIV cohort
S English*1, A Winter2, R Nandwani2, A MacConnachie1, A Seaton1 and 
R Fox1
Address: 1Brownlee Centre, Glasgow, UK and 2Sandyford Centre, Glasgow, UK
* Corresponding author    
Purpose of the study
HIV-related cardiovascular morbidity is increasingly rec-
ognised. Myocardial infarction (MI) is common in the
West of Scotland, thus cardiac events in patients with HIV
are of particular interest. This study aimed to estimate the
prevalence of MI in the Glasgow HIV cohort, comparing
the characteristics of MI patients with an HIV-positive
control group.
Methods
We searched our unit's HIV database to identify cases of
MI. Each case was matched for age, sex, and ethnicity to
two HIV-positive controls. Data were recorded at the time
of MI in the cases and at the same date in the matched
controls.
Summary of results
Of 947 HIV-positive patients in the database, 19 (2%) had
experienced an MI. Case notes for three patients were
unobtainable, leaving 16 cases and 32 controls for review.
All cases were male, with a median age of 45 yrs at the
time of MI. Fourteen cases (87.5%) were of white UK ori-
gin and 13 cases (81%) were MSM. Median CD4 count
was 322 cells/cmm and median HIV viral load (VL) was
36,500 copies/ml at HIV diagnosis in the MI group. Myo-
cardial infarction occurred before HIV diagnosis in one
case and within a year of diagnosis in three cases. Median
time from HIV diagnosis to MI was 9 yrs in the remaining
12 cases. Eleven cases were on HAART at the time of MI,
with a median treatment length of 6.7 yrs. Abacavir was
included in the treatment regimen of four cases (25%) at
the time of MI and by seven controls (22%) at the corre-
sponding time point. Didanosine was used by four cases
(25%) at the time of MI and by three controls (9%). Cur-
rent smoking was more common amongst the MI cases
(81% vs. 37%). Diabetes mellitus was also more frequent
in the MI group (25% vs. 15%). Whilst median total cho-
lesterol was similar between the cases and controls (5.9 vs.
5.05 mmol/l), median total triglyceride was higher in the
MI group (2.95 vs. 1.85 mmol/l). Hypertension was
recorded in 31% of the MI group and in 28% of controls.
Insufficient data were recorded on family history. Eighty-
seven percent of MI cases take regular aspirin at present.
Currently, 69% of MI cases are prescribed a statin and an
ACE-inhibitor. There have been no MI-related deaths,
however, three MI cases (19%) have required coronary
artery by-pass grafting.
Conclusion
The prevalence of MI in our HIV cohort is 2%. Rates of
smoking and diabetes are higher in the MI group, high-
lighting the need to address risk factor modification more
aggressively and increase the use of secondary prevention.
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